Research programme: cell therapies - AstraZeneca/Cellectis
Latest Information Update: 15 Jan 2024
At a glance
- Originator Cellectis
- Developer AstraZeneca; Cellectis
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer; Immunological disorders